Charles R Conway
Overview
Explore the profile of Charles R Conway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Leon V, Allen R, Quevedo J, Riva-Posse P, Aaronson S, Berger M, et al.
J Affect Disord
. 2024 Dec;
374:619-629.
PMID: 39722333
Background: Suicide attempts are a major concern in major depressive disorder (MDD), especially for those with multiple prior unsuccessful treatment trials. This report compares baseline demographic, clinical features, and treatment...
2.
Conway C, Aaronson S, Sackeim H, George M, Zajecka J, Bunker M, et al.
Brain Stimul
. 2024 Dec;
PMID: 39706521
Background: Few treatments are available for individuals with marked treatment-resistant depression (TRD). Objective: Evaluate the safety and effectiveness of FDA-approved adjunctive vagus nerve stimulation (VNS) in patients with marked TRD....
3.
Rush A, Conway C, Aaronson S, George M, Riva-Posse P, Dunner D, et al.
Brain Stimul
. 2024 Dec;
PMID: 39701918
Background: Depression treatments aim to minimize symptom burden and optimize quality of life (QoL) and psychosocial function. Objective: Compare the effects of adjunctive versus sham vagus nerve stimulation (VNS) on...
4.
Conway C, Palanca B, Zeffiro T, Gott B, Brown F, de Leon V, et al.
medRxiv
. 2024 Aug;
PMID: 39185528
While nitrous oxide (NO) has demonstrated antidepressant properties in treatment-resistant major depression (TRD), little is known about neural mechanisms mediating these effects. Employing serial resting-state functional magnetic resonance imaging (rs-fMRI),...
5.
Sackeim H, Aaronson S, Bunker M, Conway C, George M, McAlister-Williams R, et al.
J Psychiatr Res
. 2024 Jun;
176:325-337.
PMID: 38917723
All definitions of treatment-resistant depression (TRD) require that patients have experienced insufficient benefit from one or more adequate antidepressant trials. Thus, identifying "failed, adequate trials" is key to the assessment...
6.
Conway C, Aaronson S, Sackeim H, Duffy W, Stedman M, Quevedo J, et al.
Brain Stimul
. 2024 Apr;
17(2):448-459.
PMID: 38574853
Background: RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. Objective: To describe pre-implantation baseline clinical characteristics and...
7.
Aaronson S, Sackeim H, Jiang M, Badejo S, Greco T, Bunker M, et al.
Aust N Z J Psychiatry
. 2023 Nov;
58(3):250-259.
PMID: 37927051
Objective: Characteristics of difficult-to-treat depression (DTD), including infrequent symptom remission and poor durability of benefit, compel reconsideration of the outcome metrics historically used to gauge the effectiveness of antidepressant interventions....
8.
Palanca B, Conway C, Zeffiro T, Gott B, Nguyen T, Janski A, et al.
Biol Psychiatry Glob Open Sci
. 2023 Oct;
3(4):698-704.
PMID: 37881568
Background: Nitrous oxide holds promise in the treatment of major depressive disorder. Its psychotropic effects and NMDA receptor antagonism have led to comparisons with ketamine. Despite longstanding use, persistent effects...
9.
de Leon V, Kumar A, Nagele P, Palanca B, Gott B, Janski A, et al.
J Clin Psychiatry
. 2023 Aug;
84(5).
PMID: 37585253
No abstract available.
10.
Sackeim H, Rush A, Greco T, Jiang M, Badejo S, Bunker M, et al.
Psychol Med
. 2023 Jan;
53(14):6511-6523.
PMID: 36601813
Background: In difficult-to-treat depression (DTD) the outcome metrics historically used to evaluate treatment effectiveness may be suboptimal. Metrics based on remission status and on single end-point (SEP) assessment may be...